Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871427 · ClinicalTrials.gov registry record · Phase 2
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
A Phase 2 study, sponsored by Axovant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02871427 is a Phase 2 study that was terminated before completion, run by Axovant Sciences. The registered enrollment target is 80 participants.
The verdict
NCT02871427, a Phase 2 study, was terminated before completion, sponsored by Axovant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).
Interventions
- DRUG Nelotanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871427
The ClinicalTrials.gov registry entry for NCT02871427 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelotanserin is the first listed.
NCT02871427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871427 about?
NCT02871427 is a clinical study titled "Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder". This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).
What is the current status of trial NCT02871427?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-10-20. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT02871427?
The interventions under investigation include: Nelotanserin (DRUG).
Who is sponsoring clinical trial NCT02871427?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.